From the General Medicine Division, Massachusetts General Hospital,
Medical Services and Department of Medicine, Harvard Medical School (R.S.S.,
D.E.S.), and Department of Epidemiology, Harvard School of Public Health
(D.E.S.), Boston, Mass.
Correspondence to Randall S. Stafford, MD, PhD, 50 Staniford St, 9th Floor, Boston, MA 02114. E-mail stafford{at}sol.mgh.harvard.edu
Background—Studies of selected
populations suggest that anticoagulation in atrial fibrillation is
underused and that nonclinical factors influence the use of this
stroke-preventing therapy. We wished to examine recent national trends
and predictors of warfarin sodium use in atrial fibrillation.
Methods and Results—A nationally representative
sample of office visits from the 1989 to 1996 National Ambulatory
Medical Care Surveys was used. We selected 1125 visits by patients with
atrial fibrillation, including 877 visits to cardiologists and primary
care physicians in which apparent contraindications for anticoagulation
were absent. The principal outcome measure was the proportion of visits
with warfarin reported. We analyzed trends in warfarin use and
statistically evaluated the predictors of warfarin use. Warfarin use
increased from 13% of atrial fibrillation visits in 1989 to 40% in
1993 (P for trend <.001) in patients without
contraindications. Between 1993 and 1996, however, there was no change
in warfarin use. Independent of other factors, warfarin was
significantly more likely to be reported in patients with a history of
stroke and in patients residing outside of the South.
Conclusions—Warfarin use in atrial fibrillation has not increased
recently, indicating inadequate implementation of this highly effective
therapy. Barriers to anticoagulation in real-world clinical practice
need to be identified and addressed.
© 1998 American Heart Association, Inc.
Brief Rapid Communications
Recent National Patterns of Warfarin Use in Atrial Fibrillation
Key Words: atrial fibrillation • anticoagulants • physician practice patterns
This article has been cited by other articles:
 |
|
 |
|
  R. Niska and B. Han Anticoagulation for Patients with Atrial Fibrillation in Ambulatory Care Settings J Am Board Fam Med, May 1, 2009; 22(3): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bejot, D. B. Salem, G. V. Osseby, G. Couvreur, J. Durier, C. Marie, Y. Cottin, T. Moreau, and M. Giroud Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006 Neurology, January 27, 2009; 72(4): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Rowan, D. N. Bailey, C. E. Bublitz, and R. J. Anderson Trends in Anticoagulation for Atrial Fibrillation in the U.S.: An Analysis of the National Ambulatory Medical Care Survey Database J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1561 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Shireman, J. D. Mahnken, P. A. Howard, T. F. Kresowik, Q. Hou, and E. F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest, November 1, 2006; 130(5): 1390 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kamohara, K. Fukamachi, Y. Ootaki, M. Akiyama, F. Cingoz, C. Ootaki, D. G. Vince, Z. B. Popovic, M. W. Kopcak Jr, R. Dessoffy, et al. Evaluation of a novel device for left atrial appendage exclusion: The second-generation atrial exclusion device. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, J. D'Antonio, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation Stroke, April 1, 2006; 37(4): 1075 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kamohara, K. Fukamachi, Y. Ootaki, M. Akiyama, F. Zahr, M. W. Kopcak Jr, R. Dessoffy, Z. B. Popovic, M. Daimon, D. M. Cosgrove, et al. A novel device for left atrial appendage exclusion J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1639 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Capucci, M. Santini, L. Padeletti, M. Gulizia, G. Botto, G. Boriani, R. Ricci, S. Favale, F. Zolezzi, N. Di Belardino, et al. Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1913 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, J. B. Seward, K. R. Bailey, T. Iwasaka, and T. S.M. Tsang Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study Stroke, November 1, 2005; 36(11): 2362 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Lin Reviewing the reality: why we need to change Eur. Heart J. Suppl., June 1, 2005; 7(suppl_E): E15 - E20. [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Scholten, A. S. Thornton, J. M. Mekel, P. J. Koudstaal, and L. J. Jordaens Anticoagulation in atrial fibrillation and flutter Europace, January 1, 2005; 7(5): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J L Martins, K F Fox, D A Wood, D C Lefroy, T J Collier, and N S Peters Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study Heart, August 1, 2004; 90(8): 877 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Hanna, P. Kolm, R. Martin, M. Reisman, W. Gray, and P. C. Block Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): Six-month echocardiographic follow-up J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1868 - 1872. [Abstract] [Full Text] [PDF]
|
|